Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04357717 · ClinicalTrials.gov registry record
ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting
A clinical trial, sponsored by Exosome Diagnostics.
- Terminated
- Registry status
- 150
- Enrollment target
NCT04357717 is a clinical trial that was terminated before completion, run by Exosome Diagnostics. The registered enrollment target is 150 participants.
The verdict
NCT04357717 was terminated before completion, sponsored by Exosome Diagnostics.
- TERMINATED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The study is designed to confirm the performance of the ExoDx Prostate test in prior negative biopsy patients now presenting for a repeat prostate biopsy. Note: ExoDx Prostate test results are collected for correlation to biopsy results and are not disclosed to the physician or study subject.
Interventions
- DIAGNOSTIC_TEST ExoDx Prostate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-03-15 |
| Est. Completion | 2021-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04357717
The ClinicalTrials.gov registry entry for NCT04357717 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exosome Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExoDx Prostate is the first listed.
NCT04357717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04357717 about?
NCT04357717 is a clinical study titled "ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting". The study is designed to confirm the performance of the ExoDx Prostate test in prior negative biopsy patients now presenting for a repeat prostate biopsy. Note: ExoDx Prostate test results are collected for correlation to biopsy results and are not disclosed to the physician or study subject.
What is the current status of trial NCT04357717?
This trial is currently terminated. The enrollment target is 150 participants. The study started on 2020-03-15. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT04357717?
The interventions under investigation include: ExoDx Prostate (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04357717?
This trial is sponsored by Exosome Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.